- Home
- YY vs KROS Comparison
YY vs KROS Comparison
Compare YY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YY
- KROS
- Stock Information
- Founded
- YY 2005
- KROS 2015
- Country
- YY Singapore
- KROS United States
- Employees
- YY N/A
- KROS N/A
- Industry
- YY EDP Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- YY Technology
- KROS Health Care
- Exchange
- YY Nasdaq
- KROS Nasdaq
- Market Cap
- YY 2.2B
- KROS 633.5M
- IPO Year
- YY 2012
- KROS 2020
- Fundamental
- Price
- YY $39.78
- KROS $15.92
- Analyst Decision
- YY Hold
- KROS Buy
- Analyst Count
- YY 3
- KROS 11
- Target Price
- YY $35.00
- KROS $68.83
- AVG Volume (30 Days)
- YY 697.4K
- KROS 1.9M
- Earning Date
- YY 11-26-2024
- KROS 02-26-2025
- Dividend Yield
- YY 2.01%
- KROS N/A
- EPS Growth
- YY N/A
- KROS N/A
- EPS
- YY 3.11
- KROS N/A
- Revenue
- YY $2,258,181,000.00
- KROS $651,000.00
- Revenue This Year
- YY $0.62
- KROS $224.66
- Revenue Next Year
- YY $1.84
- KROS N/A
- P/E Ratio
- YY $13.44
- KROS N/A
- Revenue Growth
- YY N/A
- KROS 8037.50
- 52 Week Low
- YY $27.88
- KROS $15.33
- 52 Week High
- YY $42.88
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- YY 51.17
- KROS 22.66
- Support Level
- YY $40.27
- KROS $15.33
- Resistance Level
- YY $42.88
- KROS $17.25
- Average True Range (ATR)
- YY 1.79
- KROS 1.37
- MACD
- YY -0.07
- KROS -0.48
- Stochastic Oscillator
- YY 60.61
- KROS 10.31
About YY JOYY Inc.
JOYY Inc is a global technology company offering comprehensive innovation capabilities. The company enables users to interact with others in real time. The group is actively exploring and expanding its global commerce Software-as-a-Service and solutions business. JOYY emphasizes technological innovation and is recognized in the industry for its significant number of patent applications and licenses.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.